Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaki Ri

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
International Journal of Hematology|June 24, 2017
Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation studyShinsuke Iida, Kenshi Suzuki, Shigeru Kusumoto, et al.
Internal Medicine (Tokyo, Japan)|December 12, 2017
A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple MyelomaMasaki Ri, Kenshi Suzuki, Shinsuke Iida, et al.
International Journal of Hematology|May 21, 2017
Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myelomaMasaki Ri, Kosei Matsue, Kazutaka Sunami, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|August 9, 2019
Plasma cell myeloma positive for t(14;20) with relapse in the central nervous systemTakayuki Murase, Atsushi Inagaki, Ayako Masaki, et al.
International Journal of Hematology|July 12, 2023
Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myelomaYoko Nakanishi, Yoshiaki Marumo, Masaki Ri, et al.
International Journal of Hematology|July 19, 2022
A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1)Kentaro Hirade, Shigeru Kusumoto, Akihiro Abe, et al.
Cancer Science|August 25, 2019
Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myelomaKeiko Maekawa, Masaki Ri, Miki Nakajima, et al.
International Journal of Hematology|September 23, 2022
Recurrent pain attacks during romiplostim treatment in a patient with ITP carrying a heterozygous MEFV mutationShiori Kinoshita, Hirokazu Komatsu, Haruna Fujinami, et al.
Human Pathology|March 10, 2012
Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specifiedSeiji Yamada, Fumihiko Sato, Hongjing Xia, et al.
Plos One|May 9, 2018
Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myelomaTakashi Yoshida, Masaki Ri, Shiori Kinoshita, et al.
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
International Journal of Hematology|June 24, 2017
Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation studyShinsuke Iida, Kenshi Suzuki, Shigeru Kusumoto, et al.
Internal Medicine (Tokyo, Japan)|December 12, 2017
A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple MyelomaMasaki Ri, Kenshi Suzuki, Shinsuke Iida, et al.
International Journal of Hematology|May 21, 2017
Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myelomaMasaki Ri, Kosei Matsue, Kazutaka Sunami, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|August 9, 2019
Plasma cell myeloma positive for t(14;20) with relapse in the central nervous systemTakayuki Murase, Atsushi Inagaki, Ayako Masaki, et al.
International Journal of Hematology|July 12, 2023
Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myelomaYoko Nakanishi, Yoshiaki Marumo, Masaki Ri, et al.
International Journal of Hematology|July 19, 2022
A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1)Kentaro Hirade, Shigeru Kusumoto, Akihiro Abe, et al.
Cancer Science|August 25, 2019
Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myelomaKeiko Maekawa, Masaki Ri, Miki Nakajima, et al.
International Journal of Hematology|September 23, 2022
Recurrent pain attacks during romiplostim treatment in a patient with ITP carrying a heterozygous MEFV mutationShiori Kinoshita, Hirokazu Komatsu, Haruna Fujinami, et al.
Human Pathology|March 10, 2012
Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specifiedSeiji Yamada, Fumihiko Sato, Hongjing Xia, et al.
Plos One|May 9, 2018
Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myelomaTakashi Yoshida, Masaki Ri, Shiori Kinoshita, et al.
Pageof 12